Boston Scientific Buys $1.5B Stake in TAVR Developer MiRus

Why It Matters

The investment restores Boston Scientific’s presence in the fast‑expanding TAVR space, positioning it to compete with Edwards Lifesciences and Medtronic while leveraging MiRus’s innovative valve design.

Key Takeaways

• Boston Scientific pays $1.5B for 34% of MiRus.
• Option to buy remaining TAVR assets for up to $3B.
• New nickel‑free balloon TAVR valve targets low‑to‑high risk patients.
• Move revives Boston’s strategy after abandoning Acurate and Lotus programs.

Pulse Analysis

The transcatheter aortic valve replacement market has surged past $10 billion globally, driven by an aging population and a shift toward minimally invasive cardiac procedures. Boston Scientific’s earlier attempts with the Acurate Neo2 and Lotus Edge fell short, prompting the company to withdraw from the segment and focus on other vascular therapies. By securing a sizable minority stake in MiRus, Boston re‑enters a market where Edwards Lifesciences and Medtronic dominate, aiming to capture a share of the projected compound annual growth rate of roughly 12% through 2035.

MiRus’s Siegel valve distinguishes itself with a nickel‑free, balloon‑expandable platform designed for patients across the risk spectrum. Early trial data suggest favorable hemodynamic performance and a lower incidence of conduction disturbances compared with existing devices. The STAR pivotal trial, evaluating three valve sizes, will provide the clinical evidence needed for U.S. FDA approval and broader European adoption. If successful, the valve could address concerns about metal allergies and streamline implantation, offering physicians a compelling alternative to current self‑expanding and balloon‑expandable options.

Strategically, Boston’s $1.5 billion stake is projected to be immaterial to 2026 adjusted earnings per share, reflecting a long‑term play rather than immediate profit. The optional $3 billion buyout gives Boston a clear pathway to full ownership, potentially unlocking synergies in manufacturing, distribution, and R&D. Moreover, the exclusive rights to MiRus’s mitral and tricuspid assets could broaden Boston’s heart‑valve portfolio, strengthening its competitive moat and providing a diversified revenue stream as the TAVR market matures.

Deal Summary

Boston Scientific announced it has invested $1.5 billion to acquire a 34% equity stake in MiRus, a developer of a balloon‑expandable transcatheter aortic valve replacement (TAVR) system. The deal includes an exclusive option for Boston Scientific to purchase the remaining business for up to $3 billion, subject to milestones. The investment aims to re‑enter the TAVR market after previous product setbacks.